Iproniazid

Summary

Iproniazid (CHEMBL92401) is an approved small molecule (ATC N06AF05); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AF05
• Indications: 1 condition
• Chemistry: 179.22 Da · C9H13N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL92401
Name	Iproniazid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3748
ATC	N06AF05
Molecular formula	C9H13N3O
Molecular weight	179.22
InChIKey	NYMGNSNKLVNMIA-UHFFFAOYSA-N

SMILES: CC(C)NNC(=O)C1=CC=NC=C1

IUPAC name: N’-propan-2-ylpyridine-4-carbohydrazide

Also known as: Iproniazid, Iproniazida, Iproniazide, Marsilid, Isonicotinic acid N’-isopropyl-hydrazide, iproniazide, iproniazid, N’-isopropylisonicotinohydrazide, SID90341605, SID11111333, SID11111334, SID50111104

Parent form; salt/anhydrous children: CHEMBL1256361, CHEMBL1534878

Patent coverage: 1,178 distinct patent families (4,730 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Prostaglandin G/H synthase 2, Amine oxidase [flavin-containing] B, Amine oxidase [flavin-containing] A, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 168 potent at pChembl ≥ 5 of 169 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.35	AC50	450	nM	CHEMBL_ACT_25174132
MAOA	6.08	IC50	837	nM	CHEMBL_ACT_17961001
MAOB	6.01	IC50	985	nM	CHEMBL_ACT_17961023
MAOB	5.9	IC50	1260	nM	CHEMBL_ACT_25507084
MAOB	5.87	IC50	1350	nM	CHEMBL_ACT_18496194
MAOB	5.87	IC50	1350	nM	CHEMBL_ACT_18891103
MAOB	5.87	IC50	1350	nM	CHEMBL_ACT_19097994
MAOB	5.87	IC50	1350	nM	CHEMBL_ACT_23179173
MAOA	5.86	IC50	1370	nM	CHEMBL_ACT_18014340
MAOA	5.86	IC50	1370	nM	CHEMBL_ACT_20658171
MAOA	5.85	IC50	1410	nM	CHEMBL_ACT_20706652
MAOB	5.79	IC50	1620	nM	CHEMBL_ACT_19092411
MAOB	5.75	IC50	1780	nM	CHEMBL_ACT_18158371
MAOB	5.75	IC50	1760	nM	CHEMBL_ACT_18223031
MAOB	5.75	IC50	1780	nM	CHEMBL_ACT_18223184
MAOB	5.75	IC50	1780	nM	CHEMBL_ACT_19051280
MAOA	5.72	IC50	1920	nM	CHEMBL_ACT_25507108
MAOB	5.71	IC50	1950	nM	CHEMBL_ACT_16544361
MAOB	5.71	IC50	1950	nM	CHEMBL_ACT_16827851
MAOB	5.71	IC50	1950	nM	CHEMBL_ACT_16840708
MAOB	5.71	IC50	1950	nM	CHEMBL_ACT_18006877
MAOB	5.71	IC50	1950	nM	CHEMBL_ACT_18574243
MAOB	5.71	IC50	1970	nM	CHEMBL_ACT_22813988
MAOA	5.63	IC50	2320	nM	CHEMBL_ACT_18223001
MAOB	5.63	IC50	2340	nM	CHEMBL_ACT_20706659
MAOA	5.59	IC50	2560	nM	CHEMBL_ACT_16544340
MAOA	5.59	IC50	2560	nM	CHEMBL_ACT_16827830
MAOA	5.59	IC50	2560	nM	CHEMBL_ACT_16840696
MAOA	5.59	IC50	2560	nM	CHEMBL_ACT_18006874
MAOA	5.59	IC50	2560	nM	CHEMBL_ACT_18574230

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).